Nutritional Priorities to Support GLP-1 Therapy A pragmatic approach to nutrition and lifestyle counseling and support is recommended to maximize benefits, minimize potential risks, and increase efficiency of GLP-1 therapy for weight reduction
Neither renal composite 1 (40% eGFR decline, RRT, or renal death) nor composite 2 (composite 1 variables plus macroalbuminuria) was reduced by exenatide in unadjusted analyses
Antacids such as Tums can help short-term
Answer: Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Victoza, Saxenda), and orforglipron (Foundayo), have become increasingly popular for obesity treatment (Mehrtash, JAMA Intern Med 2025)
Under ad libitum feeding conditions, we found that heart, body, and heart/body weights and nonfasting tail blood glucose measurements were not affected by treatment assignment (Supplemental Figure 1
These pleiotropic effects highlight their potential to transform precision medicine across a spectrum of metabolic and non-metabolic diseases